AstraZeneca Pharma India Wins New Approval for Calquence Use in Untreated CLL and SLL

AstraZeneca Pharma India Limited ( (IN:ASTRAZEN) ) has shared an announcement.

AstraZeneca Pharma India has received permission from India’s Central Drugs Standard Control Organisation to import Acalabrutinib 100 mg tablets, marketed as Calquence, for an additional indication in combination with venetoclax with or without obinutuzumab. The new approval allows the company to market Calquence in India for treating previously untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma, potentially strengthening its oncology portfolio and expanding access to advanced blood cancer therapies, subject to further statutory clearances.

This regulatory milestone may bolster AstraZeneca Pharma India’s competitive positioning in the domestic cancer therapeutics space by broadening its indicated use of a key targeted therapy. For stakeholders, the permission signals a deeper push into high-value oncology treatments that could support future revenue growth and reinforce the company’s role in meeting unmet clinical needs in haematological malignancies.

More about AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited operates in the pharmaceutical industry, focusing on the import, marketing, and distribution of innovative prescription medicines in India. The company’s portfolio covers key therapeutic areas such as oncology and other specialty segments, aligning its offerings with advanced global treatments adapted for the Indian market.

Average Trading Volume: 394

Technical Sentiment Signal: Buy

Current Market Cap: 201.4B INR

See more data about ASTRAZEN stock on TipRanks’ Stock Analysis page.